5/21/2023 0 Comments You are the placebo book![]() ![]() ![]() ![]() One advantage of that model, in theory, is that it somewhat insulates the company from the massive stock drops that tend to happen when biotechs strike out on clinical trials, as it often doesn't own 100% of the organizations running the trials. That effectively means its business model is to fund research and development (R&D) on its behalf. Atai doesn't have any recurring revenue as of yet, and it probably won't until it can commercialize a drug within the next few years. It also has minority stakes in other operators like Compass Pathways that are doing the same type of development. In case you aren't familiar, Atai is a biotech that's developing a handful of mental health treatments based on psychedelic molecules like MDMA via several subsidiaries and variable-interest entities. ![]()
0 Comments
Leave a Reply. |